Affymax, Inc. is a biopharmaceutical company previously committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision was to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers before a nationwide voluntary recall of OMONTYS® (peginesatide) Injection in February 2013. In March 2013 Affymax commenced a review of strategic alternatives.
|Type||Public / Private|
Top 5 Recent Tweets
|August 29, 2020||TickerReport||Affymax $AFFY Stock Passes Above 200-Day Moving Average of $0.03 https://t.co/6A00XxpENk|
|August 29, 2020||dailypoliticaln||Affymax $AFFY Stock Passes Above 200 Day Moving Average of $0.03 https://t.co/zVVI0QXjPy|
|August 24, 2020||Jasik||$AFFY 0.08 (+71.67%) $89,335 $/v with 121 trades today. https://t.co/eUw718hHal https://t.co/xtSF9hgtRD|